Key Developments: Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

8.40USD
1:46pm EDT
Change (% chg)

$0.05 (+0.54%)
Prev Close
$8.36
Open
$8.50
Day's High
$8.53
Day's Low
$8.26
Volume
597,704
Avg. Vol
1,288,390
52-wk High
$14.20
52-wk Low
$6.33

Search Stocks

Latest Key Developments (Source: Significant Developments)

Inovio Pharmaceuticals Inc partners with GeneOne Life Science for MERS immunotherapy clinical development
1:00am EDT 

Inovio Pharmaceuticals Inc:Says it will advance its DNA vaccine for MERS (Middle East Respiratory Syndrome) into a phase I clinical trial in healthy volunteers in a collaboration with GeneOne Life Science Inc, an international DNA vaccine developer and manufacturer in which Inovio holds an equity interest.MERS is a respiratory disease caused by a coronavirus, which is related to the severe acute respiratory syndrome (SARS) virus.MERS carries a 40% death rate; there is no vaccine or effective treatment for this virus.Inovio and GeneOne will conduct a phase I trial to evaluate the safety, tolerability and immunogenicity of Inovio's DNA-based MERS vaccine.  Full Article

Inovio Pharmaceuticals Inc closes $87.4 million underwritten financing
Tuesday, 5 May 2015 12:19pm EDT 

Inovio Pharmaceuticals Inc:Closed its underwritten public offering of 10,925,000 shares of the company's common stock, including 1,425,000 shares of common stock issued pursuant to the underwriter's exercise of its option, at the public offering price of $8.00 per share.The gross proceeds of this offering were $87.4 million.Net proceeds to the company, after deducting the underwriter's discounts and commission and other estimated offering expenses payable by the company, were about $82.1 million.The company intends to use the net proceeds received from the sale of the common stock for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, manufacturing expenses and.potential acquisitions of companies and technologies that complement its business.Piper Jaffray & Co. and Stifel acted as joint bookrunning managers for the offering. H.C. Wainwright & Co., LLC, Brean Capital, LLC and Maxim Group LLC acted as co-managers of the offering.  Full Article

Inovio Pharmaceuticals Inc announces pricing of public offering of common stock
Thursday, 30 Apr 2015 09:00am EDT 

Inovio Pharmaceuticals Inc:Pricing of an underwritten public offering of 9,500,000 shares of common stock for a public offering price of $8.00 per share.Gross proceeds to Inovio from this offering are expected to be $76,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.Company has granted to underwriters participating in the offering a 30-day option to purchase up to an additional 1,425,000 shares of common stock.Offering is expected to close on or about May 5 subject to customary closing conditions.  Full Article

Inovio Pharmaceuticals Inc announces public offering of common stock
Wednesday, 29 Apr 2015 04:01pm EDT 

Inovio Pharmaceuticals Inc:Intends to offer and sell shares of common stock in an underwritten public offering.Piper Jaffray & Co. and Stifel are acting as joint bookrunning managers for the offering.  Full Article

Inovio Pharmaceuticals and Roche Initiate Clinical Trial for Inovio's DNA Immunotherapy to Treat Chronic Hepatitis B Infection
Tuesday, 21 Apr 2015 03:00am EDT 

Inovio Pharmaceuticals Inc:Initiates a phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B.In 2013, Roche and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy.Trial initiation triggers a $3 mln milestone payment from Roche to Inovio.  Full Article

Inovio Pharmaceuticals Inc initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers
Thursday, 18 Dec 2014 06:00am EST 

Inovio Pharmaceuticals Inc:Says it has initiated a phase I trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with Inovio's IL-12 immune activator (INO-9012) in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments.Says study will be conducted at the University of Pennsylvania's Abramson Cancer Center, which will fund all site-specific clinical study costs.Says this study will evaluate Inovio's novel immunotherapy with the ultimate goal of reducing the risk of relapse in these patients.Says primary objective of this study is to evaluate the safety and tolerability of INO-1400 alone or in combination with INO-9012, delivered intramuscularly in subjects with high-risk breast, lung, or pancreatic cancer with no evidence of disease after surgery and adjuvant therapy.Says the secondary objectives are to evaluate cellular and humoral immune responses, measure time to disease progression, and evaluate immunotherapy-induced changes in subjects.  Full Article

Inovio Pharmaceuticals added to NASDAQ Biotechnology Index
Monday, 15 Dec 2014 08:00am EST 

Inovio Pharmaceuticals:Says it has been added to the NASDAQ Biotechnology Index (NBI).The addition to the NASDAQ Biotechnology Index will become effective upon market open on Dec. 22.  Full Article

Inovio Pharmaceuticals Inc ebola vaccine moving into human trial with GeneOne Life Science
Wednesday, 24 Sep 2014 06:00am EDT 

Inovio Pharmaceuticals Inc:Says it will advance its DNA vaccine for Ebola into a phase I clinical trial in collaboration with GeneOne Life Science Inc.Says collaboration Inovio and GeneOne will co-develop Inovio's DNA-based Ebola vaccine through a phase I clinical trial.Says companies are currently conducting pre-IND activities and plan to start the clinical study in the first half of 2015.Says upon successful completion of the phase I, the companies will jointly seek additional third party support and resources to further develop and commercialize this product.  Full Article

Inovio Pharmaceuticals Inc expands HPV Immunotherapy development to Aerodigestive Cancers
Monday, 22 Sep 2014 08:00am EDT 

Inovio Pharmaceuticals Inc:Initiates phase I clinical trial in patients with aerodigestive cancers.The trial will evaluate the safety, tolerability, and immunogenicity of INO-3106.This immunotherapy targets human papillomavirus type 6 (HPV-6), which causes most aerodigestive cancers.Aerodigestive cancers affect the lips, mouth, tongue, nose, throat, vocal cords, and parts of the esophagus and windpipe.Unmet need for patients suffering from this form of cancer is significant.This study is part of Inovio's strategy to broadly expand clinical development of its DNA-based immune therapy products to treat different HPV types and the many diseases they cause.It is a phase I, open label compassionate study enrolling patients with invasive cancer who have exhausted all other treatment options (chemotherapy, radiation and surgery).Study will test Inovio's immunotherapy, INO-3106, alone or in combination with DNA-based IL-12, Inovio's proprietary immune activator, in subjects with HPV-6 associated aerodigestive malignancies.Successful results could open a path to pursuing an FDA orphan designation (special status granted for therapies for rare diseases) for aerodigestive cancers.  Full Article

Inovio Pharmaceuticals begins trading on NASDAQ Global Select Market Exchange
Monday, 15 Sep 2014 08:59am EDT 

Inovio Pharmaceuticals Inc:Met the stringent listing criteria for the NASDAQ Global Select Market and has transferred to this U.S. stock exchange from the NYSE MKT.Company will continue to trade under its current ticker symbol, "INO.".  Full Article

Search Stocks